As per NAVADHI Market Research, the global pharmaceutical industries will us worth USD 1.57 trillion by 2023. The growth in this market is predicted on the basis of various factors like market drivers, current and upcoming trends, current growth pattern, and market challenges. North America is e...
The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals ...
Discover the burgeoning pharmaceutical landscape in the heart of the Middle East, where Saudi Arabia stands as a beacon of opportunity. Explore new frontiers and understand the potential for innovation and growth in this dynamic market.
1. Pharmaceutical Analytical Testing Outsourcing Market Size, Share & Trends Analysis Report By Service, 2023-2030, Grand View Research, April 15, 2023. 2. Global Pharmaceutical Analytical Testing Outsourcing Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report, 2023-2028, Market ...
In the US, recent reports by Manhattan Research have found that more than 81 per cent of physicians use a smartphone, up from 72 per cent in 2010. Another study found that 96 per cent of all healthcare organizations surveyed said that they had experienced at least one data breach in the...
2020 was a big year for market access initiatives in the UK, many of which are only just starting, and their impact will come through in 2021 and beyond. Looking back at key market access news from 2020, Leela Barham takes stock of what 2021 could bring
Artificial intelligence canreduce drug discovery costs by up to 70%according to a recent study by Insider Intelligence AI cansave pharma $28 billion a yearon clinical research while cutting the phase’s length by half AI can spare pharma companiesup to $54 billion annuallyon R&D costs ...
as examples when describing barriers to entry.1Most countries have some barriers to the entry of the legal drug sector due to the research and manufacturing startup costs, but the U.S.Food and Drug Administration(FDA) and significant health care regulations make the U.S. a special case.2 ...
advance the field especially for individuals whose lives have been severely disrupted by the disease by approving two cell-based gene therapies today," Dr Nicole Verdun, director of the Office of Therapeutic Products in the FDA’s Center for Biologics Evaluation and Research, said in a statement....
It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies.